Skip to main content
. 2020 Oct 29;34(6):809–823. doi: 10.1007/s40259-020-00447-6

Fig. 5.

Fig. 5

Mean change in CRP and ESR levels over 48 weeks (SP2 PPS). a CRP, b ESR. Dotted lines indicate the treatment switch from ref-ADL group to SDZ-ADL group. CRP C-reactive protein, ESR erythrocyte sedimentation rate, ref-ADL reference adalimumab, SDZ-ADL Sandoz biosimilar adalimumab, SP2 PPS study period 2 per protocol set